Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | POLA1 | P09884 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4576226 | 0.95 | PDE3A (0.68) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Phosphoric Acid SCHEMBL20769284 | 0.95 | PDE3A (0.68) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Cytidine SCHEMBL7192541 | 0.91 | LMNA (0.77) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL16130206 | 0.89 | PDE3A (0.76) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL6843762 | 0.89 | PDE3A (0.76) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL1880453 | 0.88 | PDE3A (0.74) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL1865151 | 0.87 | PDE3A (0.58) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12151832 | 0.86 | PDE3A (0.72) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12150864 | 0.86 | PDE3A (0.72) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL21006620 | 0.86 | PDE3A (0.72) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| WO-2023154964-A1 | METHODS AND COMPOSITIONS FOR TARGETING EFEMP1 | ALLOY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| WO-2021117122-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY SYNDROME | 株式会社リボルナバイオサイエンス | 2021-06-17 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-8110560-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2012-02-07 | — | — | US | claimed |
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-7838657-B2 | compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (intronic splicing silencer), located in the SMN2 gene | UNIVERSITY OF MASSACHUSETTS (US) | 2010-11-23 | — | — | US | claimed |
| US-20100087511-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2010-04-08 | — | — | US | claimed |
| US-20070292408-A1 | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2007-12-20 | — | — | US | claimed |
| EP-1556402-A4 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIV MASSACHUSETTS (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1556402-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | University of Massachusetts (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |
| WO-2003012052-A2 | SPECIFIC INHIBITION OF GENE EXPRESSION BY SMALL DOUBLE STRANDED RNAS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-02-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | SMN1; SMN2, MSI2, RBM17 | PDE3A 4063/4885PDE4D 3795/4885SLC29A1 2384/4885 |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | PDE3A 4790/4885PDE4D 4322/4885SLC29A1 268/4885 |
| US-20050020521-A1 | Rna interference strands and antibody strands | AGO2, NSUN3, NSUN2 | PDE3A 4774/4885PDE4D 4013/4885SLC29A1 348/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | PDE3A 4790/4885PDE4D 4322/4885SLC29A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.